Clinical Trial Detail

NCT ID NCT02413853
Title Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Southern California
Indications

colorectal adenocarcinoma

Therapies

Bevacizumab

PRI-724

Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab

Age Groups: adult

No variant requirements are available.